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Abstract
Haematopoietic stem cell transplantation (HSCT) has evolved from an experimental concept to an
effective treatment option for severe autoimmune diseases and has a unique ability to restore
immune regulation. It is a complex multistep procedure involving the administration of high doses of
immunosuppressive medication and transplantation of stem cells. Most HSCT procedures in
autoimmune disease have involved autologous stem cells. In the case of allogeneic transplantation,
stem cells are derived from peripheral blood or bone marrow of a healthy HLA-matched donor.
Allogeneic HSCT has curative potential based on studies in experimental models of autoimmune
disease, case reports, and a registry analysis but carries significant risks of rejection and graft-versus-
host disease. Unless these risks become manageable, allogeneic HSCT should be offered only if all
alternative treatment options have failed, if a patient has a suitable donor, and if a patient still has a
chance to benefit significantly from the procedure.
Introduction and context
Allogeneic haematopoietic stem cell transplantation
(HSCT), or ‘allografting’, is an established treatment for
haematological malignancies and genetic defects, but
not autoimmune diseases (ADs). The risk of graft-versus-
host disease (GvHD) and the difficulties in finding a
suitable donor have hampered clinical studies on
allografting in AD. Yet there is a good scientific rationale
for allografting in AD as it theoretically is the only
treatment of AD with curative potential. Its main aim is
to replace a patient’s dysfunctional immune system with
an allograft from a healthy donor so as to restore normal
immune regulation. This is in contrast with autologous
HSCT, in which a patient’s own stem cells are re-infused
after intensive immunosuppressive therapy. In patients
with a haematological condition and concomitant AD
such as rheumatoid arthritis (RA) or systemic lupus
erythematosus (SLE), allografting resulted in long-term
improvements of disease activity [1,2]. Extensive studies
in different animal models of AD have confirmed the
superiority of allografting in eliminating reactivity
against autoantigens and inducing sustained clinical
responses [3]. The term ‘graft-versus-autoimmunity’
(GvA) effect has been coined, in analogy to the ‘graft-
versus-leukaemia’ effect observed in allotransplanted
leukaemia patients, to describe the reactivity of donor T
and natural killer cells against a patient’s autoreactive
lymphocytes [4]. Whether GvA can occur in the absence
of (sub)clinical GvHD is a matter of debate but is an
important issue as it would not make sense to exchange
one AD for another.
Recent advances
Feasibility and safety of allografting have improved
significantly since allogeneic bone marrow transplanta-
tion was first introduced in the clinic in the 1950s. This
can be explained by the use of less intensive regimens
and a switch from whole bone marrow transplants to
T cell-depleted peripheral blood stem cell grafts [5].
Nowadays, so-called non-myeloablative preparative
regimens that leave stem cells intact, permitting rapid
reconstitution of innate immune cells and thus reducing
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of T cell-depleted allografts for haemato-oncological
indications has reduced the risk of GvHD but at the
expense of a higher risk of relapse. While undesirable,
such an outcome is probably preferred over serious
complications from GvHD in the case of AD. Despite its
theoretical appeal, allografting is still used only inciden-
tally to treat AD, and most cases have involved patients
with multiple sclerosis, RA, SLE, vasculitis or systemic
sclerosis (SSc). Both long-term remissions and relapses
have been observed [1,7-9]. Remarkably, in two patients
with severe SSc, non-myeloablative conditioning
resulted in 10-15% donor chimerism yet was sufficient
to achieve complete sustained remission for more than
3 years after HSCT [10,11]. This suggested that full
ablation of the host immune system is not a pre-
condition to induce effective immune regulation. Similar
observations were made in a patient with severe
refractory RA treated with non-myeloablative condition-
ing and HLA-matched CD34-selected HSCT [12]. This
patient was in remission with 55% donor T cells and
70% donor myeloid cells in blood. Systematic studies in
experimental animal AD have confirmed that low levels
(>1%) of allogeneic haematopoietic chimerism are
sufficient to treat AD effectively [13]. In a recent review
of the EBMT (European Group for Blood and Marrow
Transplantation) Database, the outcome reports of
35 patients who had haematological or non-haemato-
logical AD and who collectively had received a total of
38 allogeneic transplantations were analysed [14]. The
group included two patients with Behçet disease, two
with vasculitis, two with SLE, one with dermatomyositis,
and four with RA. An impressive 55% of patients
reportedly had a complete response and 23% had at
least a partial response, with a median duration of
response of 12.3 months after HSCT. This came at the
expense of a treatment-related mortality at 2 years of
22.1%, however. The probability of survival at 2 years
was 70% (Figure 1). No predictive factor of survival
could be identified. Although based on a retrospective
analysis of partly incomplete data, the induction of
complete remission by allografting underscores the
potential clinical effectiveness. A recent proof-of-principle
study in mice showed that it is possible to achieve donor
stem cell engraftment in bone marrow via antibody-
based clearance of haematopoietic stem cell niches. If
applicable in humans, this would bypass the need for
preparative regimens based on chemotherapy and reduce
toxicity [15].
Implications for clinical practice
Allogeneic HSCT may be considered for poor-prognosis
patients who have failed conventional treatment includ-
ing biologicals (RA or juvenile idiopathic arthritis) or
autologous HSCT (SSc or SLE), which is now being
examined in prospective clinical trials. Nevertheless, the
clinical evidence in favour of allografting is sparse and
the risks are considerable. In our opinion, patients with
end-stage disease or serious co-morbidities should not
be transplanted. The risks of HSCT in general (both
autologous and allogeneic) may be particularly high in
patients who have been heavily pre-treated with different
immunosuppressive drugs, including biologicals, or who
suffer from severe organ damage (or both). Patient
selection is therefore critical and patients should be
offered HSCT only if they have treatment-resistant life-
threatening disease yet a reasonable lifespan to allow
logistical preparations for HSCT to be made. Patients
should also have acceptable organ function to withstand
unintended consequences of intensive immunosuppres-
sive treatment and be willing to accept the risks of
allografting. In terms of donor selection, sibling or
matched unrelated donor transplants are preferred to
minimise the risk of GvHD. There is no consensus (yet)
about the optimal transplant regimen or even the source
Figure 1. Allogeneic haematopoietic stem cell transplantation in
autoimmune disease
(a) Kaplan-Meier plot of survival for all patients with autoimmune disease
(n = 35) treated with allogeneic haematopoietic stem cell transplantation.
CI, confidence interval. (b) Cumulative incidence of death owing to disease
progression versus transplant-related mortality. Originally published in
Daikeler et al. [14], Bone Marrow Transpl 2009.
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outweigh the risks can be investigated only through a
prospective collaborative trial with standardised treat-
ment regimens, uniform eligibility criteria and outcome
measures, but whether such a trial is feasible remains to
be seen. In the interim, it would probably be best to
harmonise treatment protocols and outcome measures
and collect outcome data from a comparator group of
patients who are considered eligible but who do not have
a suitable donor.
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